

CITATION REPORT

List of articles citing

Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer

DOI: 10.1016/j.hemonc.2018.04.002
Hematology/ Oncology and Stem Cell Therapy, 2019,
12, 1-9.

Source: <https://exaly.com/paper-pdf/71819589/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
3	Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. <i>Targeted Oncology</i> , 2019 , 14, 1-12	5	8
2	Everolimus plus endocrine vs endocrine therapy in treatment advanced ER+, HER2- breast cancer patients: A meta-analysis. <i>Current Problems in Cancer</i> , 2019 , 43, 106-114	2.3	2
1	Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors?. <i>Future Oncology</i> , 2020 , 16, 1851-1862	3.6	1